Study Evaluating Oral MOA-728 in Subjects on Methadone Therapy

Phase 1

Withdrawn

• Conditions: Methadone-maintenance Subjects

• Registration Number: NCT00505583
• Lead Sponsor: Bausch Health Americas, Inc.

Brief Summary

To evaluate the effects of single oral doses of MOA-728 compared to a positive control in subjects on methadone therapy.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-07
• Study First Submitted: 2007-07-16
• Study First Submitted QC: 2007-07-20
• Study First Posted: 2007-07-23
• Primary Completion: 2007-12
• Study Completion: 2007-12
• Status Verified: 2019-11
• Last Update Submitted: 2019-11-26
• Last Update Posted: 2019-11-29

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
To characterize the pharmacodynamics of single oral doses of MOA-728 compared to a positive control of MOA-728 administered intravenously in subjects on stable methadone maintenance.